Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Core Scientific Inc . (NASDAQ:CORZ), currently trading at $14.83 and rated "Fair" by InvestingPro’s comprehensive health assessment, has received a reiterated Outperform rating and $17.00 price target from Bernstein SocGen Group.
The rating confirmation comes as CoreWeave announced its acquisition of Core Scientific in an all-stock deal, valuing CORZ at approximately $9 billion in equity value.
Core Scientific stock fell approximately 13% following the acquisition news, despite having gained nearly 50% since June 26 when acquisition rumors first emerged.
Bernstein analyst Gautam Chhugani suggested the market reaction stemmed from investors possibly expecting a higher valuation and disappointment with the all-stock structure of the deal, which is set to close in Q4.
The analyst noted investor concerns may relate to the absence of price protection in the deal structure and the delayed closure timeline, especially considering CoreWeave’s stock has already tripled in value year-to-date.
In other recent news, CoreWeave has announced an all-stock acquisition of Core Scientific, valuing the company at $20.40 per share. This transaction, which is expected to close in the fourth quarter of 2025, will result in Core Scientific shareholders owning approximately 10% of the combined entity. Following the announcement, BTIG downgraded Core Scientific from Buy to Neutral, citing unmet investor expectations for a cash component in the deal. DA Davidson reiterated an Underperform rating on CoreWeave, noting the acquisition will eliminate over $10 billion in future lease overhead. Jefferies suggested the acquisition could strategically benefit CoreWeave by expanding its data center capabilities and reducing reliance on third-party developers. Additionally, Cantor Fitzgerald maintained an Overweight rating on Core Scientific, emphasizing the undervaluation of its partnership with CoreWeave and the potential growth in AI and high-performance computing sectors. The firm also highlighted Core Scientific’s profitable Bitcoin mining operations, which could provide significant upside potential. These developments reflect ongoing strategic maneuvers and analyst evaluations in the evolving landscape of both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.